Drs. Takako Shintani and Chika Ohata contributed equally in this study.
Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis
Article first published online: 17 SEP 2013
© 2013 Wiley Periodicals, Inc.
Volume 27, Issue 3, pages 135–139, May/June 2014
How to Cite
Shintani, T., Ohata, C., Koga, H., Ohyama, B., Hamada, T., Nakama, T., Furumura, M., Tsuruta, D., Ishii, N. and Hashimoto, T. (2014), Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. Dermatologic Therapy, 27: 135–139. doi: 10.1111/dth.12094
- Issue published online: 5 JUN 2014
- Article first published online: 17 SEP 2013
- Ministry of Education, Culture, Sports, Science and Technology. Grant Numbers: 20390308, 20591331, 21659271, 23591634, 23791298, 23791299, 23791300, 23791301, 24659534, 24591672, 24591640, 24791185
- Ministry of Health, Labour and Welfare. Grant Numbers: H23-028, H24-038
- Kaibara Morikazu Medical Science Promotion Foundation
- Ishibashi Foundation
- Kanae Foundation for the Promotion of Medical Science
- Takeda Science Foundation
- Chuo Mitsui Trust and Banking Company, Limited
- Nakatomi Foundation
- combination therapy;
- pemphigoid nodularis;
- prurigo nodularis
In this study, we report on the efficacy of combination therapy of second-generation antihistamine antagonist, fexofenadine hydrochloride, and leukotriene receptor inhibitor, montelukast sodium, for the treatment of 15 prurigo nodularis or pemphigoid nodularis patients, in whom conventional therapy was ineffective. All patients received 10 mg montelukast once a day and 240 mg fexofenadine twice a day for 4 weeks in addition to other medications they had been taking. We assessed the manifestations of the lesions and itching intensity before and after the therapy, and we evaluated each patient as (i) markedly improved, (ii) improved, (iii) slightly improved, (iv) no change, (v) worse. Two patients (13.3%) were evaluated as markedly improved, and the lesions of one patient completely disappeared. Three patients (20.0%) were evaluated as improved, and six patients (40.0%) as slightly improved. Thus, 11 of 15 cases (73.3%) improved by combination therapy of fexofenadine and montelukast, in which nine cases (75.0%) of prurigo nodularis and two cases (66.7%) of pemphigoid nodularis were involved. No patients revealed any side effects. This study revealed that combination therapy of fexofenadine and montelukast was effective for some patients with conventional therapy-resistant prurigo nodularis and pemphigoid nodularis.